CLAIM CARD
The evidence base for glycation-related interventions on cardiometabolic outcomes includes two clinical RCTs and four observational cohorts. Movahedian 2025 reported a dose of 5 mg. Ozdemir 2025 compared a low-AGEs diet to a standard-AGEs-containing weight-loss diet in overweight women with polycystic ovary syndrome (PCOS), examining metabolic and hormonal profiles. Vazquez-Agra 2025 conducted an observational study linking glycated hemoglobin (HbA1c) levels to short-term blood pressure variability in young and middle-aged nondiabetic hypertensive individuals. Ustkoyuncu 2025 performed a case-control study comparing soluble receptor for advanced glycation end product (sRAGE) levels in adolescents with insulin resistance, those without insulin resistance, and healthy controls.
Evidence grade: exploratory
Contradiction status: none
Publication: 88f190ad-b3cd-4533-8b95-219d3a357339
Provenance: Derivation Web chain
Citation Support
source_1Movahedian 2025source_2Kopytek 2025source_3Chang 2025source_4Wu 2025source_5Li 2026